Inovio Pharmaceuticals
INO
96 hedge funds and large institutions have $65.1M invested in Inovio Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 22 closing their positions.
48% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $1.98M
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
15% more capital invested
Capital invested by funds: $56.4M → $65.1M (+$8.72M)
13.69% more ownership
Funds ownership: 17.4% → 31.1% (+14%)
8% more funds holding
Funds holding: 89 → 96 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$21.7M |
| 2 |
BlackRock
New York
|
+$14.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.69M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.47M |
| 5 |
Bank of New York Mellon
New York
|
+$861K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.55M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.11M |
| 3 |
HF
HRT Financial
New York
|
-$1.06M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$722K |
| 5 |
MTIM
Marathon Trading Investment Management
Radnor,
Pennsylvania
|
-$421K |
INO Hedge Fund Activity: Q2 2024 in Review
96 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2024, worth a combined $65.1M — up 15% from $56.4M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new INO positions and 22 closed out — a net gain of 8 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $21.7M. The largest seller was Millennium Management, cutting an estimated $2.55M.
- 96 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2024, up from 89 in Q1 2024.
- Funds reported $65.1M of Inovio Pharmaceuticals stock for Q2 2024, up 15% quarter-over-quarter.
- 30 funds opened new Inovio Pharmaceuticals positions in Q2 2024 and 22 closed out, a net change of +8 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2024 was Deep Track Capital, an estimated $21.7M added.
- The largest Inovio Pharmaceuticals seller in Q2 2024 was Millennium Management, an estimated $2.55M sold.
Based on aggregated 13F filings for Q2 2024.